{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:24:27Z","timestamp":1790393067827,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatic metastases of GIST might be the dominant site of progression and resistant to available tyrosine kinase inhibitors (TKIs). Selective internal radiation therapy (SIRT) offers treatment by intratumoral radiation up to 200\u2009Gy. We analyzed the hepatic progression-free survival (H-PFS) in a consecutive patient cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twenty-six patients (median age 57.6 years) with biopsy proven liver metastases of GIST were treated by SIRT. All had RECIST documented tumor progression, and 24\/26 patients had up to four lines of pretreatment. Mutational status was \u2018quadruple wildtype\u2019 (q-wt,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095), KIT exon 11\/9\/13 in\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915\/4\/1 cases and PDGFR\u03b1 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091). Median follow-up of this retrospective analysis of a prospectively kept database is 33.6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median H-PFS was 16 months (range, 4\u201354+ months, 95% CI 6.5\u201325.4 months) and OS after SIRT was 28 months (95% CI 17.2\u201328.7 months). Best H-PFS was observed in patients with \u2018q-wt\u2019 at 25 months (range, 6+\u201354 months, 95% CI 16.2\u201333.8 months). The worst outcome was for KIT exon 11 mutations plus secondary mutations with 7 months (range, 4\u201333 months, 95% CI, 4.2\u20139.8 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>90Y-SIRT is a potent treatment for patients with liver metastases of GIST resistant to TKI therapy. In patients with \u2018q-wt\u2019 GIST, SIRT is an option for first-line use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-02952-3","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T06:25:45Z","timestamp":1741155945000},"page":"716-724","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Selective internal radiation with Y-90 resin microspheres (SIRT) for liver metastases of gastro-intestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy"],"prefix":"10.1038","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-5923","authenticated-orcid":false,"given":"Peter","family":"Hohenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Rathmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"B\u00fcsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franka","family":"Menge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-4910","authenticated-orcid":false,"given":"Eva","family":"Wardelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen J.","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2952_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5131-4","volume":"18","author":"M Ressing","year":"2018","unstructured":"Ressing M, Wardelmann E, Hohenberger P, Jakob J, Kasper B, Emrich K, et al. Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. BMC Public Health. 2018;18:235.","journal-title":"BMC Public Health"},{"key":"2952_CR2","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","volume":"130","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466\u201378.","journal-title":"Arch Pathol Lab Med"},{"key":"2952_CR3","doi-asserted-by":"crossref","unstructured":"Vassos N, Jakob J, Kahler G, Reichardt P, Marx A, Dimitrakopoulou-Strauss A, et al. Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy. Cancers. 2021;13:586.","DOI":"10.3390\/cancers13040586"},{"key":"2952_CR4","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127\u201334.","journal-title":"Lancet"},{"key":"2952_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329\u201338.","journal-title":"Lancet"},{"key":"2952_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295\u2013302.","journal-title":"Lancet"},{"key":"2952_CR7","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.22.00294","volume":"40","author":"S Bauer","year":"2022","unstructured":"Bauer S, Jones RL, Blay JY, Gelderblom H, George S, Schoffski P, et al. Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022;40:3918\u201328.","journal-title":"J Clin Oncol"},{"key":"2952_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00280-013-2135-8","volume":"72","author":"S Patel","year":"2013","unstructured":"Patel S. Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol. 2013;72:277\u201386.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2952_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamaoncol.2016.6728","volume":"3","author":"MC Heinrich","year":"2017","unstructured":"Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, et al. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017;3:944\u201352.","journal-title":"JAMA Oncol"},{"key":"2952_CR10","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ejca.2015.02.015","volume":"51","author":"CK Lee","year":"2015","unstructured":"Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, et al. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. Eur J Cancer. 2015;51:852\u201360.","journal-title":"Eur J Cancer"},{"key":"2952_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"MC Heinrich","year":"2020","unstructured":"Heinrich MC, Jones RL, von Mehren M, Schoffski P, Serrano C, Kang YK, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21:935\u201346.","journal-title":"Lancet Oncol"},{"key":"2952_CR12","doi-asserted-by":"crossref","unstructured":"Mathias-Machado MC, de Jesus VHF, de Carvalho Oliveira LJ, Neumann M, Peixoto RD. Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications. Cancers. 2022;14:5330.","DOI":"10.3390\/cancers14215330"},{"key":"2952_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1075-6","volume":"14","author":"E Shi","year":"2016","unstructured":"Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, et al. FGFR1 and NTRK3 actionable alterations in \u201cWild-Type\u201d gastrointestinal stromal tumors. J Transl Med. 2016;14:339.","journal-title":"J Transl Med"},{"key":"2952_CR14","doi-asserted-by":"publisher","first-page":"e8240","DOI":"10.1097\/MD.0000000000008240","volume":"96","author":"YN Shi","year":"2017","unstructured":"Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, et al. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China. Medicine. 2017;96:e8240.","journal-title":"Medicine"},{"key":"2952_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","volume":"33","author":"PG Casali","year":"2022","unstructured":"Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:20\u201333.","journal-title":"Ann Oncol"},{"key":"2952_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11864-021-00837-0","volume":"22","author":"JA Yonkus","year":"2021","unstructured":"Yonkus JA, Alva-Ruiz R, Grotz TE. Surgical Management of Metastatic Gastrointestinal Stromal Tumors. Curr Treat Options Oncol. 2021;22:37.","journal-title":"Curr Treat Options Oncol"},{"key":"2952_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cam4.325","volume":"4","author":"MA Pantaleo","year":"2015","unstructured":"Pantaleo MA, Nannini M, Corless CL, Heinrich MC. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med. 2015;4:101\u20133.","journal-title":"Cancer Med"},{"key":"2952_CR18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/1078-0432.CCR-16-0152","volume":"23","author":"D Gasparotto","year":"2017","unstructured":"Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, et al. Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome. Clin Cancer Res. 2017;23:273\u201382.","journal-title":"Clin Cancer Res"},{"key":"2952_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/fon-2016-0192","volume":"13","author":"Z Szucs","year":"2017","unstructured":"Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13:93\u2013107.","journal-title":"Future Oncol"},{"key":"2952_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(05)70097-8","volume":"6","author":"E Wardelmann","year":"2005","unstructured":"Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6:249\u201351.","journal-title":"Lancet Oncol"},{"key":"2952_CR21","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12:1743\u20139.","journal-title":"Clin Cancer Res"},{"key":"2952_CR22","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. lancet oncology. 2020;21:e18\u2013e28.","journal-title":"lancet oncology"},{"key":"2952_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"2952_CR24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00261-016-0687-x","volume":"41","author":"PJ Littrup","year":"2016","unstructured":"Littrup PJ, Aoun HD, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series. Abdom Radiol (NY). 2016;41:767\u201380.","journal-title":"Abdom Radiol (NY)"},{"key":"2952_CR25","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.jvir.2015.09.002","volume":"26","author":"JH Jung","year":"2015","unstructured":"Jung JH, Won HJ, Shin YM, Kim PN. Safety and Efficacy of Radiofrequency Ablation for Hepatic Metastases from Gastrointestinal Stromal Tumor. J Vasc Interv Radiol. 2015;26:1797\u2013802.","journal-title":"J Vasc Interv Radiol"},{"key":"2952_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ejso.2009.12.005","volume":"36","author":"RL Jones","year":"2010","unstructured":"Jones RL, McCall J, Adam A, O\u2019Donnell D, Ashley S, Al-Muderis O, et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol. 2010;36:477\u201382.","journal-title":"Eur J Surg Oncol"},{"key":"2952_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3852420","volume":"2020","author":"C Sutton","year":"2020","unstructured":"Sutton C, Zhang Y, Kim D, Yarmohammadi H, Ziv E, Boas FE, et al. Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. Sarcoma. 2020;2020:3852420.","journal-title":"Sarcoma"},{"key":"2952_CR28","doi-asserted-by":"crossref","unstructured":"Boshell D, Bester L. Radioembolisation of liver metastases. J Med Imaging Radiat Oncol. 2023;67:842\u201352.","DOI":"10.1111\/1754-9485.13549"},{"key":"2952_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12876-023-02793-5","volume":"23","author":"JC Alonso","year":"2023","unstructured":"Alonso JC, Casans I, Gonzalez FM, Fuster D, Rodriguez A, Sanchez N, et al. Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review. BMC Gastroenterol. 2023;23:181.","journal-title":"BMC Gastroenterol"},{"key":"2952_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jvir.2014.09.020","volume":"26","author":"N Rathmann","year":"2015","unstructured":"Rathmann N, Diehl SJ, Dinter D, Schuette J, Pink D, Schoenberg SO, et al. Radioembolization in patients with progressive gastrointestinal stromal tumor liver metastases undergoing treatment with tyrosine kinase inhibitors. J Vasc Interv Radiol. 2015;26:231\u20138.","journal-title":"J Vasc Interv Radiol"},{"key":"2952_CR31","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1002\/cncr.34931","volume":"129","author":"CL Hallemeier","year":"2023","unstructured":"Hallemeier CL, Sharma N, Anker C, Selfridge JE, Lee P, Jabbour S, et al. American Radium Society Appropriate Use Criteria for the use of liver-directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines. Cancer. 2023;129:3193\u2013212.","journal-title":"Cancer"},{"key":"2952_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0041-1732323","volume":"38","author":"LA Webster","year":"2021","unstructured":"Webster LA, Villalobos A, Majdalany BS, Bercu ZL, Gandhi RT, Kokabi N. Standard Radiation Dosimetry Models: What Interventional Radiologists Need to Know. Semin Intervent Radiol. 2021;38:405\u201311.","journal-title":"Semin Intervent Radiol"},{"key":"2952_CR33","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","volume":"25","author":"H Choi","year":"2007","unstructured":"Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753\u20139.","journal-title":"J Clin Oncol"},{"key":"2952_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","volume":"13","author":"H Choi","year":"2008","unstructured":"Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist. 2008;13:4\u20137.","journal-title":"Oncologist"},{"key":"2952_CR35","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/ijc.35094","volume":"155","author":"M Meyer","year":"2024","unstructured":"Meyer M, Ota H, Messiou C, Benson C, Henzler T, Mattonen SA, et al. Prospective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy-Impact on clinical outcome. Int J Cancer. 2024;155:2047.","journal-title":"Int J Cancer"},{"key":"2952_CR36","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","volume":"25","author":"A Trotti","year":"2007","unstructured":"Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121\u20137.","journal-title":"J Clin Oncol"},{"key":"2952_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00000658-196508000-00018","volume":"162","author":"IM Ariel","year":"1965","unstructured":"Ariel IM. Treatment of Inoperable Primary Pancreatic and Liver Cancer by the Intra-Arterial Administration of Radioactive Isotopes (Y90 Radiating Microspheres). Ann Surg. 1965;162:267\u201378.","journal-title":"Ann Surg"},{"key":"2952_CR38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/jso.2930200304","volume":"20","author":"IM Ariel","year":"1982","unstructured":"Ariel IM, Padula G. Treatment of asymptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. J Surg Oncol. 1982;20:151\u20136.","journal-title":"J Surg Oncol"},{"key":"2952_CR39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.critrevonc.2011.01.012","volume":"80","author":"V Goffredo","year":"2011","unstructured":"Goffredo V, Paradiso A, Ranieri G, Gadaleta CD. Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Crit Rev Oncol Hematol. 2011;80:393\u2013410.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2952_CR40","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jvir.2018.01.775","volume":"29","author":"MD Miller","year":"2018","unstructured":"Miller MD, Sze DY, Padia SA, Lewandowski RJ, Salem R, Mpofu P, et al. Response and Overall Survival for Yttrium-90 Radioembolization of Hepatic Sarcoma: A Multicenter Retrospective Study. J Vasc Interv Radiol. 2018;29:867\u201373.","journal-title":"J Vasc Interv Radiol"},{"key":"2952_CR41","doi-asserted-by":"crossref","unstructured":"Testa S, Bui NQ, Wang DS, Louie JD, Sze DY, Ganjoo KN. Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas. Cancers. 2022;14:324.","DOI":"10.3390\/cancers14020324"},{"key":"2952_CR42","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00330-005-2647-7","volume":"15","author":"K Sandrasegaran","year":"2005","unstructured":"Sandrasegaran K, Rajesh A, Rushing DA, Rydberg J, Akisik FM, Henley JD. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol. 2005;15:1407\u201314.","journal-title":"Eur Radiol"},{"key":"2952_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.18383\/j.tom.2017.00007","volume":"3","author":"M Patel","year":"2017","unstructured":"Patel M, Jilani D, Oto A, Patel P. Evaluating the Sensitivity of Arterial Phase CT Images for Detection of Hepatic GIST Metastases. Tomography. 2017;3:101\u20134.","journal-title":"Tomography"},{"key":"2952_CR44","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1148\/radiol.2353040332","volume":"235","author":"S Shankar","year":"2005","unstructured":"Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005;235:892\u20138.","journal-title":"Radiology"},{"key":"2952_CR45","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/1078-0432.CCR-04-2046","volume":"11","author":"U De Giorgi","year":"2005","unstructured":"De Giorgi U, Aliberti C, Benea G, Conti M, Marangolo M. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2005;11:6171\u20136.","journal-title":"Clin Cancer Res"},{"key":"2952_CR46","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2214\/AJR.21.26636","volume":"218","author":"M Meyer","year":"2022","unstructured":"Meyer M, Hohenberger P, Overhoff D, Bartsch A, Henzler T, Haubenreisser H, et al. Dual-Energy CT Vital Iodine Tumor Burden for Response Assessment in Patients With Metastatic GIST Undergoing TKI Therapy: Comparison With Standard CT and FDG PET\/CT Criteria. AJR Am J Roentgenol. 2022;218:659\u201369.","journal-title":"AJR Am J Roentgenol"},{"key":"2952_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40336-017-0229-8","volume":"5","author":"A Dimitrakopoulou-Strauss","year":"2017","unstructured":"Dimitrakopoulou-Strauss A, Ronellenfitsch U, Cheng C, Pan L, Sachpekidis C, Hohenberger P, et al. Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clin Transl Imaging. 2017;5:183\u201397.","journal-title":"Clin Transl Imaging"},{"key":"2952_CR48","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1148\/radiol.2016160143","volume":"281","author":"AD Smith","year":"2016","unstructured":"Smith AD, Zhang X, Bryan J, Souza F, Roda M, Sirous R, et al. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy. Radiology. 2016;281:484\u201398.","journal-title":"Radiology"},{"key":"2952_CR49","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s00270-023-03391-4","volume":"46","author":"G Maleux","year":"2023","unstructured":"Maleux G, Albrecht T, Arnold D, Bargellini I, Cianni R, Helmberger T, et al. Predictive Factors for Adverse Event Outcomes After Transarterial Radioembolization with Yttrium-90 Resin Microspheres in Europe: Results from the Prospective Observational CIRT Study. Cardiovasc Intervent Radiol. 2023;46:852\u201367.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2952_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.gie.2009.03.015","volume":"70","author":"A Konda","year":"2009","unstructured":"Konda A, Savin MA, Cappell MS, Duffy MC. Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc. 2009;70:561\u20137.","journal-title":"Gastrointest Endosc"},{"key":"2952_CR51","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1634\/theoncologist.2010-0074","volume":"15","author":"KM Sjoquist","year":"2010","unstructured":"Sjoquist KM, Goldstein D, Bester L. A serious complication of selected internal radiation therapy: case report and literature review. oncologist. 2010;15:830\u20135.","journal-title":"oncologist"},{"key":"2952_CR52","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.suronc.2020.10.014","volume":"35","author":"B Laila","year":"2020","unstructured":"Laila B, Vinciane L, Michael V, Patrick F, Awada A, Maria GG, et al. Diagnosis, pathophysiology, and treatment of SIRT-induced gastroduodenal ulcers: A systematic literature review. Surg Oncol. 2020;35:520\u20136.","journal-title":"Surg Oncol"},{"key":"2952_CR53","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390554","volume":"43","author":"N Hindi","year":"2023","unstructured":"Hindi N, Laack N, Hong K, Hohenberger P. Local Therapies for Metastatic Sarcoma: Why, When, and How? Am Soc Clin Oncol Educ Book. 2023;43:e390554.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2952_CR54","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","volume":"95","author":"KA Ahmed","year":"2016","unstructured":"Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, et al. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016;95:1399\u2013404.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2952_CR55","doi-asserted-by":"crossref","unstructured":"Pezzulla D, Chiloiro G, Lima EM, Macchia G, Romano C, Reina S, et al. Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro\/eortc consensus recommendations. Clin Exp Metastasis. 2024:41:667\u201378.","DOI":"10.1007\/s10585-024-10301-6"},{"key":"2952_CR56","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1002\/cncr.22336","volume":"107","author":"K Kobayashi","year":"2006","unstructured":"Kobayashi K, Gupta S, Trent JC, Vauthey JN, Krishnamurthy S, Ensor J, et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer. 2006;107:2833\u201341.","journal-title":"Cancer"},{"key":"2952_CR57","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2214\/AJR.16.17573","volume":"210","author":"DB Pierce","year":"2018","unstructured":"Pierce DB, Johnson GE, Monroe E, Loggers ET, Jones RL, Pollack SM, et al. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018;210:175\u201382.","journal-title":"AJR Am J Roentgenol"},{"key":"2952_CR58","first-page":"124","volume":"26","author":"G Cao","year":"2014","unstructured":"Cao G, Zhu X, Li J, Shen L, Yang R, Chen H, et al. A comparative study between Embosphere((R)) and conventional transcatheter arterial chemoembolization for treatment of unresectable liver metastasis from GIST. Chin J Cancer Res. 2014;26:124\u201331.","journal-title":"Chin J Cancer Res"},{"key":"2952_CR59","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1097\/JS9.0000000000001077","volume":"110","author":"H Wen","year":"2024","unstructured":"Wen H, Huang Y, Huang S, Xiao H, Xie W, Zhou Q, et al. The long-term efficacy of imatinib with hepatic resection or other local treatment for gastrointestinal stromal tumours liver metastases: a retrospective cohort study. Int J Surg. 2024;110:2151\u201361.","journal-title":"Int J Surg"},{"key":"2952_CR60","doi-asserted-by":"crossref","unstructured":"Brink P, Kalisvaart GM, Schrage YM, Mohammadi M, Ijzerman NS, Bleckman RF, et al. Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry. Eur J Surg Oncol. 2023;49:106942.","DOI":"10.1016\/j.ejso.2023.05.017"},{"key":"2952_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(20)30393-9","volume":"6","author":"M Ronot","year":"2021","unstructured":"Ronot M, Levy V, Nault JC. Personalised dosimetry for SIRT: new standard or bridge to surgical resection? Lancet Gastroenterol Hepatol. 2021;6:161.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2952_CR62","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2967\/jnumed.119.238808","volume":"61","author":"L Gruber","year":"2020","unstructured":"Gruber L, Jimenez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, et al. MITIGATE-NeoBOMB1, a Phase I\/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients. J Nucl Med. 2020;61:1749\u201355.","journal-title":"J Nucl Med"},{"key":"2952_CR63","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2147\/CMAR.S232936","volume":"12","author":"J Yang","year":"2020","unstructured":"Yang J, Yan J, Zeng M, Wan W, Liu T, Xiao JR. Bone Metastases of Gastrointestinal Stromal Tumor: A Review of Published Literature. Cancer Manag Res. 2020;12:1411\u20137.","journal-title":"Cancer Manag Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02952-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02952-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02952-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T07:01:44Z","timestamp":1744614104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-02952-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,5,3]]}},"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-02952-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was obtained from: The Medical Ethics Commission II, Medical Faculty Mannheim of the University of Heidelberg, Maybachstr. 14, 68169 Mannheim. Application date July 31\n                      st\n                      2023, reference #168995-AF 11, title of the project submitted: \u2018Predictive factors of longterm survival in metastatic GIST (Analyse determinierender Faktoren des Langzeit\u00fcberlebens bei Patienten mit metastasiertem Gastrointestinalen Stromatumor)\u2019. The study was granted August 24\n                      th\n                      , 2023 registration #857-23. All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all participants. No identifiable images from human research participants are part of this report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}